Drug Discovery World

DECEMBER 13, 2023

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

Pharmaceutical Technology

FEBRUARY 3, 2023

“For each production process, you have to generate the plasmids in huge quantities with GMP quality and then do a transient transfection, meaning you mix them with a transfection reagent and add that to the cells in a very controlled way,” explains Faust. Cytiva and the Drop logo are trademarks of Life Sciences IP Holdings Corp.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

OCTOBER 13, 2022

The DDW team spent 4-5 October, 2022 at ELRIG’s annual meeting, Drug Discovery 2022, which remains Europe’s largest meeting for life sciences industry professionals and took place at ExCel, London, UK.

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

Drug Discovery World

OCTOBER 21, 2022

Accordingly, advances in flow cytometry technology – both in instrumentation and reagent offerings – are enabling researchers to decipher these questions, leading to new discoveries and diagnostic tools. . Best antibody development practices are summarised in Fig. Overview, evolution, trends .

Reagent 52

Reagent Antibody Drugs Protein 52

Drug Discovery World

SEPTEMBER 28, 2022

To further streamline the customer experience, optimised reagent kits with validated antibodies from PerkinElmer’s BioLegend business are also part of the solution. . ” .

Gene Therapy 52

Gene Therapy Manufacturing Gene Reagent 52

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

FEBRUARY 27, 2023

“We’re transforming drug discovery, and it all begins in the lab where researchers can leverage multimode plate reader technology like the EnVision Nexus system to increase R&D productivity at nearly every stage of their process,” said PerkinElmer Senior Vice President of Life Sciences Alan Fletcher. “By

Drugs 52

Drugs Life Science Protein Scientist 52

Drug Discovery World

FEBRUARY 15, 2023

These have been the most promising form of antibodies being developed, with Ipilimumab (CTLA4 blocking) and Nivolumab (PD1 blocking) now approved by the US Food and Drug Administration (FDA) for more than nine cancer types. Besides spheroids, another area of interest is antibody-directed cell cytotoxicity (ADCC).

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

JULY 18, 2023

Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases. Another promising approach consists of conjugating antibodies, such as an anti-CD38, to the LNPs for targeted delivery into specific tissues.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

OCTOBER 20, 2022

Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done. For imaging mass cytometry, heavy metal-conjugated antibodies are added simultaneously to a tissue section adhered to a slide.

Antibody 52

Antibody In-Vivo Life Science Development 52